

26 May 2026

CORIS® Commercialisation Milestones Progressing as Planned

- Second FDA 510(k) submission made for expanded scope indications
- First Australian CMR unit installed: Clinical training underway with commencement imminent
- UK Controlled Market release progressing in line with expectations

Nanosonics Limited (ASX: NAN), a leader in infection prevention solutions, today provides an update on progress against key milestones in the phased commercialisation of its CORIS® system.

The Company has successfully submitted its second FDA 510(k) application, supporting further expansion of CORIS' endoscope indications. This follows the previously announced first 510(k) clearance and represents continued progress in building a broad range of endoscope indications as part of the broader commercialisation strategy.

In parallel, Nanosonics continues to advance its Controlled Market Release (CMR) program. In Australia, the first CORIS unit has now been installed, with hospital staff currently undergoing training, and the CMR expected to commence shortly.

The UK CMR remains underway, with CORIS operating in line with expectations. Additional sites in Australia and Ireland are planned to come online progressively, with US CMR activities to follow initial learnings from these early deployments.

"We are making good progress across our phased commercialisation plan for CORIS. The submission of our second 510(k), together with the advancement of our CMR programs, reflects disciplined execution against our regulatory and market entry strategy," said Michael Kavanagh, CEO & President of Nanosonics.

About the CORIS system & CMR

The CORIS system is a novel technology designed to reduce infection risk and enhance patient safety by delivering improved cleaning outcomes for flexible endoscopes, in particular, the complex channels of endoscopes which are prone to biofilm build up. Through an automated mechanism of action, CORIS combines cutting-edge science and engineering with practical usability to address what is recognised as one of the most critical challenges in medical device reprocessing today.

Nanosonics' CMR is the first step of its phased commercialisation of the CORIS system. It involves a strategically limited launch into select user environments to generate real-world feedback, helping the Company identify and resolve any potential unexpected issues prior to broader commercialisation in FY27.

For more information, please contact:

Catherine Strong, Head of Investor Relations and Corporate Communications
+61 (0)406 759 268, c.strong@nanosonics.com

Authorised by the Chairman of Nanosonics Limited.

CORIS® is a registered trade mark of Nanosonics Limited.